Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor

Journal of Receptors and Signal Transduction

Volumn 29, Issue 2, 2009, Pages 107-112

  Langenheim, John Fairbanks ^a,b   Chen, Wen Yuan ^a,b  

^a University Medical Group   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Growth hormone; Growth hormone receptor; Heterodimer; Prolactin; Prolactin receptor

Indexed keywords

GROWTH HORMONE RECEPTOR; HETERODIMER; HYBRID PROTEIN; JANUS KINASE 2; PROLACTIN RECEPTOR; PROTEIN B2036 PROTEIN G129R FUSION PROTEIN; RECEPTOR BLOCKING AGENT; STAT5 PROTEIN; UNCLASSIFIED DRUG; LIGAND;

ANIMAL CELL; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; JANUS KINASE 2; LIGANDS; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; RATS; RECEPTORS, PROLACTIN; RECEPTORS, SOMATOTROPIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 68949175303     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890902845252     Document Type: Article

References (44)

1. Keeler C, Dannies PS, Hodsdon ME. The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 2003, 328, 1105-1121
2. Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB. Solution structure of human prolactin. J Mol Biol 2005, 351, 810-823
3. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 1992, 255, 306-312
4. Chantalat L, Jones N, Korber F, Navaza J, Pavlovsky AG.The crystal-structure of wild-type growth-hormone at 2.5 angstrom resolution. Protein peptide Lett 1995, 2, 333-340
5. Clackson T, Wells JA. A hot spot of binding energy in a hormonereceptor interface. Science 1995, 267, 383-386
6. Walsh ST, Kossiakoff AA. Crystal structure and site 1 binding energetics of human placental lactogen. J Mol Biol 2006, 358, 773-784
7. Nicola NA, Hilton DJ. General classes and functions of four-helix bundle cytokines. Adv Protein Chem 1998, 52, 1-65
8. Sakal E, Bignon C, Grosclaude J, Kantor A, Shapira R, Leibovitch H, Helman D, Nespoulous C, Shamay A, et al. Large-scale preparation and characterization of recombinant ovine placental lactogen. J Endocrinol 1997, 152, 317-327
9. Byatt JC, Eppard PJ, Veenhuizen JJ, Curran TL, Curran DF, McGrath MF, Collier RJ. Stimulation of mammogenesis and lactogenesis by recombinant bovine placental lactogen in steroidprimed dairy heifers. J Endocrinol 1994, 140, 33-43
10. Herman A, Bignon C, Daniel N, Grosclaude J, Gertler A, Djiane J. Functional heterodimerization of prolactin and growth hormone receptors by ovine placental lactogen. J Biol Chem 2000, 275, 6295-6301
11. Staten NR, Byatt JC, Krivi GG. Ligand-specific dimerization of the extracellular domain of the bovine growth hormone receptor. J Biol Chem 1993, 268, 18467-18473
12. Herman A, Helman D, Livnah O, Gertler A. Ruminant placental lactogens act as antagonists to homologous growth hormone receptors and as agonists to human or rabbit growth hormone receptors. J Biol Chem 1999, 274, 7631-7639
13. Warren WC, Byatt JC, Huynh M, Paik K, Pegg G, Staten NR. Evaluation of the somatogenic activity of bovine placental lactogen with cell lines transfected with the bovine somatotropin receptor. Life Sci 1999, 65, 2755-2767
14. Biener E, Martin C, Daniel N, Frank SJ, Centonze VE, Herman B, Djiane J, Gertler A. Ovine placental lactogen-induced heterodimerization of ovine growth hormone and prolactin receptors in living cells is demonstrated by fluorescence resonance energy transfer microscopy and leads to prolonged phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT3. Endocrinology 2003, 144, 3532-3540
15. Gertler A, Biener E, Ramanujan KV, Djiane J, Herman B. Fluorescence resonance energy transfer (FRET) microscopy in living cells as a novel tool for the study of cytokine action. J Dairy Res 2005, 72, Spec No: 14-19
16. Gertler A, Djiane J. Mechanism of ruminant placental lactogen action: molecular and in vivo studies. Mol Genet Metab 2002, 75, 189-201
17. Noel S, Herman A, Johnson GA, Gray CA, Stewart MD, Bazer FW, Gertler A, Spencer TE. Ovine placental lactogen specifically binds to endometrial glands of the ovine uterus. Biol Reprod 2003, 68, 772-780
18. Dietz AB, Georges M, Threadgill DW, Womack JE, Schuler LA. Somatic cell mapping, polymorphism, and linkage analysis of bovine prolactin-related proteins and placental lactogen. Genomics 1992, 14, 137-143
19. Gootwine E, Yossafi S. Genetic mapping of the ovine placental lactogen gene to sheep chromosome 20. Anim Genet 1998, 29, 69
20. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991, 254, 821-825 (Pubitemid 21917402)
21. Sundstrom M, Lundqvist T, Rodin J, Giebel LB, Milligan D, Norstedt G.Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution. J Biol Chem 1996, 271, 32197-32203
22. Kleinberg DL, Todd J. Evidence that human growth hormone is a potent lactogen in primates. J Clin Endocrinol Metab 1980, 51, 1009-1013
23. Cunningham BC, Jhurani P, Ng P, Wells JA. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science 1989, 243, 1330-1336
24. Somers W, Ultsch M, De Vos AM, Kossiakoff AA. The X-ray structure of a growth hormone-prolactin receptor complex. Nature 1994, 372, 478-481
25. Ultsch MH, Somers W, Kossiakoff AA, de Vos AM. The crystal structure of affinity-matured human growth hormone at 2 A resolution. J Mol Biol 1994, 236, 286-299
26. Cunningham BC, Wells JA. Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci USA 1991, 88, 3407-3411
27. Kossiakoff AA, Somers W, Ultsch M, Andow K, Muller YA, De Vos AM. Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors. Protein Sci 1994, 3, 1697-1705
28. Cunningham BC, Bass S, Fuh G, Wells JA. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990, 250, 1709-1712
29. Dattani MT, Hindmarsh PC, Brook CG, Robinson IC, Weir T, Marshall NJ. Enhancement of growth hormone bioactivity by zinc in the eluted stain assay system. Endocrinology 1993, 133, 2803-2808
30. Fuh G, Colosi P, Wood WI, Wells JA. Mechanism-based design of prolactin receptor antagonists. J Biol Chem 1993, 268, 5376-5381
31. Duda KM, Brooks CL. Differential effects of zinc on functionally distinct human growth hormone mutations. Protein Eng 2003, 16, 531-534
32. Langenheim JF, Tan D, Walker AM, Chen WY. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol Endocrinol 2006, 20, 661-674
33. Yang N, Langenheim JF, Wang X, Jiang J, Chen WY, Frank SJ. Activation of growth hormone receptors by growth hormone and growth hormone antagonist dimers: insights into receptor triggering. Mol Endocrinol 2007, 22, 978-988
34. Ultsch M, de Vos AM. Crystals of human growth hormonereceptor complexes. Extracellular domains of the growth hormone and prolactin receptors and a hormone mutant designed to prevent receptor dimerization. J Mol Biol 1993, 231, 1133-1136
35. Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 1994, 269, 15892-15897
36. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992, 256, 1677-1680
37. Cunningham BC, Lowman HB, Wells JA, Clark RG, Olson K, Fuh GG, inventors; Genentech Inc, assignee. Human growth hormone variants. United States patent 5849535, 1998
38. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999, 140, 3853-3856
39. Maamra M, Finidori J, Von Laue S, Simon S, Justice S, Webster J, Dower S, Ross R. Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the fulllength human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J Biol Chem 1999, 274, 14791-14798
40. Mellado M, Rodriguez-Frade JM, Kremer L, von Kobbe C, de Ana AM, Merida I, Martinez AC. Conformational changes required in the human growth hormone receptor for growth hormone signaling. J Biol Chem 1997, 272, 9189-9196
41. Rui H, Djeu JY, Evans GA, Kelly PA, Farrar WL. Prolactin receptor triggering. Evidence for rapid tyrosine kinase activation. J Biol Chem 1992, 267, 24076-24081
42. Shiu RP, Elsholtz HP, Tanaka T, Friesen HG, Gout PW, Beer CT, Noble RL. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line. Endocrinology 1983, 113, 159-165
43. Decouvelaere C, Peyrat JP, Bonneterre J, Djiane J, Jammes H. Presence of the two growth hormone receptor messenger RNA isoforms in human breast cancer. Cell Growth Differ 1995, 6, 477-483
44. Fujikawa T, Kaneko H, Hibasami H, Sakaguchi K, Alam KS, Tanaka M, Nakashima K. Inverse effects of 20K and 22K human growth hormones on the growth of T-47D human breast cancer cells in culture and in nude mice. Biochem Mol Biol Int 1998, 46, 719-724